Have any questions? 706-721-6582 or cts@augusta.edu
- DEBIO: 1450-BJI-205: Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability and Efficacy of Afabicin IV/oral in the Treatment of Patients with Bone or Joint Infection due to Staphylococcus
Clinical Trial
DEBIO: 1450-BJI-205: Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability and Efficacy of Afabicin IV/oral in the Treatment of Patients with Bone or Joint Infection due to Staphylococcus
This study will see how safe, effective and well-tolerated the study drug Afabicin is when given IV, followed by oral treatment, in patients hospitalized with bone or joint infections from staph aureus.
Eligibility Criteria
- INCLUSION: 1. Adults with bone or joint infections caused by staph aureus 2. Have received no more than 7 days of antibiotics before beginning study drug EXCLUSION: 1. Infection from another bacterial in addition to staph 2. At risk of liver disease, or of QT changes in the ECG, as defined in the protocol 3. No medical problems, lab valuesor medications that are not allowed by the study
RESEARCH. INNOVATION. DISCOVERY.